CEBP CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rollinson, S.
Right arrow Articles by Morgan, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rollinson, S.
Right arrow Articles by Morgan, G. J.
Cancer Epidemiology Biomarkers & Prevention Vol. 13, 795-800, May 2004
© 2004 American Association for Cancer Research

High-Throughput Association Testing on DNA Pools to Identify Genetic Variants that Confer Susceptibility to Acute Myeloid Leukemia

Sara Rollinson1, James M. Allan1, Graham R. Law1, Philippa L. Roddam1, Martyn T. Smith2, Christine Skibola2, Alexandra G. Smith1, Matthew S. Forrest2, Kathryn Sibley1, Russell Higuchi3, Soren Germer3 and Gareth J. Morgan1

1 Leukaemia Research Fund Epidemiology and Genetics Unit, School of Medicine, University of Leeds, Leeds, LS2 9JT, United Kingdom; 2 Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, California; and 3 Roche Molecular Systems, Alameda, California

Requests for reprints: Gareth J. Morgan, Academic Unit of Haematology and Oncology, Algernon Firth Building, Great George Street, University of Leeds, Leeds, LS2 9JT, United Kingdom. Phone: 44-113-3433372; Fax: 44-113-3433372. E-mail: Gareth.Morgan{at}egu.leeds.ac.uk

We have evaluated the use of allele-specific PCR (AS PCR) on DNA pools as a tool for screening inherited genetic variants that may be associated with risk of adult acute myeloid leukemia (AML). Two DNA pools were constructed, one of 444 AML cases, and another of 823 matched controls. The pools were validated using individual genotyping data for GSTP1 and LT{alpha} variants. Allele frequencies for variants in GSTP1 and LT{alpha} were estimated using quantitative AS PCR, and when compared to individual genotyping data, a high degree of concordance was seen. AS primer pairs were designed for nine candidate genetic variants in DNA repair and cell cycle/apoptotic regulatory genes, including Cyclin D1 [codon 870 splice site variant (A>G)]; BRCA1, P871L; ERCC2, K751Q; FAS –1377 (G>A); hMLH1 –93 (G>A) and V219I; p21, S31R; and the XRCC1 R194W and R399Q variants. For six of these assays, there was at least 95% concordance between AS PCR genotyping and an alternative approach carried out on individual samples. Furthermore, these six AS PCR assays all accurately estimated allele frequencies in the pools that had been calculated using individual genotyping data. A significant disease association was seen with AML for the –1377 variant in FAS (odds ratio 1.76, 95% confidence interval 1.26–2.44). These data suggest that quantitative AS PCR can be used as an efficient screening technique for disease associations of genetic variants in DNA pools made from case-control studies.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2004 by the American Association for Cancer Research.